Bio News
Company presents a two-track strategy: Ritovazet for high-risk patients and Baro-ezet for those at low to moderate risk
Daewoong Pharmaceutical said its dyslipidemia combination drug Ritovazet lowers LDL-C by approximately 50% with initial administration alone. The treatment is intended for high-risk patients, while the company introduced its new product Baro-ezet for low- to moderate-risk patients, who account for more than 70% of Korean adults. The company plans to provide personalized treatment options through a portfolio of the two combination drugs.
Biobook Team
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
